Association of Molecular Characteristics with Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) are currently used as monotherapy or combination therapy in frontline and subsequent lines for metastatic lung cancer including adenocarcinoma, squamous cell carcinoma, and small cell lung cancer (SCLC) [1 –5]. Furthermore, ICIs before or after surgery showed efficacy in patients with resectable disease, highlighting the potential of ICIs to improve outcomes in these patients and expand the use of ICIs in the neoadjuvant and adjuvant settings [6,7]. Despite higher response rates, longer duration of response, and less toxicity of ICIs compared with chemotherapy, many lung cancer patients have primary and acquired resistance to ICIs.

Source: Lung Cancer - May 23, 2020 Category: Cancer & Oncology Authors: Dan Zhao, Isa Mambetsariev, Haiqing Li, Chen Chen, Jeremy Fricke, P.A. Patricia Fann, Prakash Kulkarni, Yan Xing, Peter P. Lee, Andrea Bild, Erminia Massarelli, Marianna Koczywas, Karen Reckamp, Ravi Salgia Source Type: research